The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)

Haematologica

Volumn 96, Issue 6, 2011, Pages 922-926

  Wasag, Bartosz ^a,b   Lierman, Els ^a   Meeus, Peter ^c   Cools, Jan ^a,d   Vandenberghe, Peter ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c OLV HOSPITAL   (Belgium)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

8p11 myeloproliferative syndrome (EMS); FGFR1; Myeloid and lymphoid neoplasms with FGFR1 abnormalities (ICD O 9967 3); T lymphoblastic leukemia lymphoma; TKI258; Tyrosine kinase inhibitor

Indexed keywords

CUT LIKE HOMEOBOX 1 PROTEIN; DNA BINDING PROTEIN; DOVITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; INTERLEUKIN 3; MIDOSTAURIN; S6 KINASE; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANEMIA; APOPTOSIS; ARTICLE; CASE REPORT; CHROMOSOME 8P; CHROMOSOME ANALYSIS; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 7; CHROMOSOME TRANSLOCATION 8; CUX1 FGFR1 FUSION ONCOGENE; FATALITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GROWTH INHIBITION; HUMAN; IC 50; IN VITRO STUDY; LEUKOCYTE COUNT; LYMPHATIC LEUKEMIA; LYMPHOBLASTOMA; ONCOGENE; POLYMERASE CHAIN REACTION; PROTEIN PHOSPHORYLATION; SEPTICEMIA; T LYMPHOBLASTIC LEUKEMIA LYMPHOMA; THROMBOCYTOPENIA;

ADULT; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 8; CYTOGENETICS; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; REPRESSOR PROTEINS; TRANSLOCATION, GENETIC;

EID: 79958051808     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.036558     Document Type: Article

References (21)

1. Bain BJ, Gilliland DG, Horny HP, Vardiman JW. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In: Swerdlow SH,Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid tissues. Lyon: IARC, 2008:67-74.
2. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010;41(4):461-76.
3. Macdonald D, Aguiar RC, Mason PJ, Goldman JM, Cross NC. A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia. 1995;9(10):1628-30.
4. Chen J, Deangelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci USA. 2004;101(40):14479-84.
5. Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NC. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia. 2004;18(5):962-6.
6. Lee SH, Lopes de Menezes D, Vora J, Harris A, Ye H, Nordahl L, et al. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res. 2005;11(10):3633-41.
7. Lopes de Menezes DE, Peng J, Garrett EN, Louie SG, Lee SH, Wiesmann M, et al. CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. Clin Cancer Res. 2005;11(14):5281-91.
8. Xin X, Abrams TJ, Hollenbach PW, Rendahl KG, Tang Y, Oei YA, et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res. 2006;12(16):4908-15.
9. Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P, et al. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res. 2008;14(7):2075-81.
10. Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood. 2007;110(10):3729-34.
11. Walz C, Chase A, Schoch C, Weisser A, Schlegel F, Hochhaus A, et al. The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Leukemia. 2005;19(6):1005-9.
12. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, et al. Trans - formation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17 (18):5321-33.
13. Belloni E, Trubia M, Gasparini P, Micucci C, Tapinassi C, Confalonieri S, et al. 8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes. Genes Chromosomes Cancer. 2005;42(3):320-5.
14. Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J, et al. FIP1L1- PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1- PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia. 2009; 23(5):845-51.
15. Weisberg E, Wright RD, Jiang J, Ray A, Moreno D, Manley PW, et al. Effects of PKC412, nilotinib, and imatinib against GISTassociated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology. 2006;131(6):1734-42.
16. Sansregret L, Nepveu A. The multiple roles of CUX1: insights from mouse models and cell-based assays. Gene. 2008;412(1-2):84-94.
17. Ripka S, Neesse A, Riedel J, Bug E, Aigner A, Poulsom R, et al. CUX1: target of Akt signaling and mediator of resistance to apoptosis in pancreatic cancer. Gut. 2010;59(8): 1101-10.
18. Hindersin S, Niemeyer CM, Germing U, Gobel U, Kratz CP. Mutation analysis of CUTL1 in childhood myeloid neoplasias with monosomy 7. Leuk Res. 2007;31(9): 1323-4.
19. Patrikis MI, Bryan EJ, Thomas NA, Rice GE, Quinn MA, Baker MS, et al. Mutation analysis of CDP, TP53, and KRAS in uterine leiomyomas. Mol Carcinog. 2003;37(2):61-4.
20. Lacronique V, Boureux A, Valle VD, Poirel H, Quang CT, Mauchauffe M, et al. A TELJAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278(5341):1309-12.
21. McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr isessential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993; 13(12):7587-95.